KO’KRАK BEZI SАRАTONIDА YUQORI TАNА VАZNI INDEKSINING O’SMANING NEOАDYUVАNT KIMYOTERАPIYAGA SEZUVCHАNLIGIGА TА'SIRI
##article.subject##:
: ko’krak bezi saratoni, tana vazni indeksi, neoadyuvant kimyoterapiya, fertil davr, rezistentlik##article.abstract##
: Ko’krak bezi saratonida yuqori tana vaznining o’sma hujayralari neoadyuvant kimyoterapiyaga sezuvchanligini baHolash.Kirish. Yuqori tana vazni ko’krak bezi saratoniga olib keluvchi muhim omil bo’lishi bilan birgalikda, kasallik kechuvi, progressiyasi, o’sma hujayralarining kimyoterapiya va nur terapiyaga sezuvchanligiga xam taʼsir etuvchi omildir.Material va metod. Ushbu tadqiqot ishi uchun Respublika Ixtisoslashtirilgan Onkologiya va Radiologiya Ilmiy-Amaliy Tibbiyot Markazida davolangan 24 nafar bemorning kasallik tarixlari asosida retrospektiv tadqiqot obyekti sifatida olindi. Bemorlar tana vazni indeksi ko'rsatkichiga asosan 2 ta guruhga bo'lindi: TVI≤30 (nazorat guruhi) va TVI≥30(asosiy guruh). Natija. Yuqori tana vazni indeksiga ega bemorlarda ko’rsatkichlar shuni qayd etadiki, semizlik tufayli NPXT o'tkazilgan kurslar soniga bog’lik bo’lmagan ravishda o’smaning sezuvchanligi normal tana vazni indeksiga ega bemorlarga nisbatan pastroq bo'ladi(p<0,01).Xulosa. Mazkur tadqiqot xulosalariga ko'ra, tana vazni indeksining yuqoriligi o'smahxujayrasining neoadyuvant kimyoterapiyaga nisbatan sezuvchanligini kamaytirishi o'rganildi. Shuning uchun bemorlarda o’tkaziladigan kimyoterapiya jarayonlari bilan birgalikda bemorlarga tana vaznini kamaytirish, muntazam jismoniy tarbiya va sog’lom ovqatlanish talab etiladi.
Библиографические ссылки
Renée T. Fortner, Verena Katzke, Tilman Kühn and Rudolf Kaaks. Obesity and Breast Cancer. Recent Resultsin Cancer Research 208.
Nicoletta Biglia, Elisa Peano, Paola Sgandurra, Giulia Moggio, Silvia Pecchio, Furio Maggiorotto &Piero Sismondi. Body mass index (BMI) and breast cancer: impact on tumorhistopatologic features, cancer subtypes and recurrence rate in preand postmenopausal women. Gynecological Endocrinology, 2013; 29(3): 263–267.
World Health Organization (WHO) (2008). WHO, global database on body mass index, BMI classification; 30-4-2008.
Ana Maria Gonzalez-Angulo , Flavia Morales-Vasquez, Gabriel N Hortobagyi. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22
Kuerer HM, Newman LA, Buzdar AU et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer Journal From Scientific American 1998; 4:230–236.
Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672–2685.
Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165–4174.
Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3(Suppl 2):S69–S74.
L.T.Alimkhodjaeva and others. The effect of body mass index on the clinical and morphological characteristics of breast cancer in women with metabolic syndrome. American journal of medicine and medical sciences. 2023,13(8):1118-1122.
Manuel Picon-Ruiz, PhD, Cynthia Morata-Tarifa, PhD, Janeiro J. Valle-Goffin, MD, Eitan R. Friedman, MD, and Joyce M. Slingerland Obesity and Adverse Breast Cancer Risk and Outcome: Mechanistic Insights and Strategies/ CA CANCER J CLIN 2017;00:00–00
